Cho Woo Hyun
Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan, Korea.
Division of Allergy, Pulmonary and Critical Care Medicine, Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, Korea.
J Chest Surg. 2022 Aug 5;55(4):357-360. doi: 10.5090/jcs.22.053.
Patients with severe coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS) may exhibit pulmonary fibrosis after the viral illness resolves. Some of these patients may experience severe functional lung impairment, and thus require transplants to prevent death or maintain a tolerable quality of life. Considering the reversibility of COVID-19 ARDS, lung transplant candidates are observed for 1-2 months and must be selected very carefully before transplantation. As the short-term outcomes of such patients are comparable to those of patients with other indications for transplantation, lung transplantation should be actively considered.
患有严重2019冠状病毒病（COVID-19）急性呼吸窘迫综合征（ARDS）的患者在病毒感染疾病消退后可能会出现肺纤维化。其中一些患者可能会出现严重的肺功能损害，因此需要进行移植以预防死亡或维持可耐受的生活质量。考虑到COVID-19 ARDS的可逆性，对肺移植候选者进行1至2个月的观察，并且在移植前必须非常谨慎地进行选择。由于这类患者的短期预后与其他移植适应症患者的预后相当，因此应积极考虑肺移植。
